期刊文献+

乌司他丁治疗老年脓毒症患者凝血功能障碍的疗效 被引量:12

下载PDF
导出
摘要 脓毒症是指由感染(可疑或确诊)引起的全身炎症反应综合征,严重者可导致多器官功能衰竭,是重症监护病房常见的危重症之一。随着我国进入人口老龄化,老年脓毒症患者占有很高的比例。近年来多项研究证实,凝血活化是脓毒症发生发展的重要环节,干预凝血功能障碍可有效控制过度的炎症反应,从而改善病情〔1〕。乌司他丁是一种在人类尿液中提取的可有效抑制多种蛋白酶活性的抑制剂,研究〔2〕表明乌司他丁具有维持血管内皮细胞稳定性及抗纤溶作用。
作者 孙晓琪
出处 《中国老年学杂志》 CAS CSCD 北大核心 2014年第5期1373-1374,共2页 Chinese Journal of Gerontology
  • 相关文献

参考文献5

二级参考文献11

  • 1卢涛,何正富.大剂量乌司他丁在体外循环手术中对凝血功能的影响[J].西北药学杂志,2004,19(4):180-181. 被引量:12
  • 2[2]Tanaka K,Takao M,Yada I,et al.Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery[J].J Cardiothorac Anesth,1989,3(2):181-188.
  • 3[3]Palmer RN,Gralnick HR.Cold-induced contact surface activation of the prothrombin time in whole blood[J].Blood,1982,59(1):38-42.
  • 4[4]Chandler WL,Velan T.Plasmin generation and D-dimer formation during cardiopulmonary bypass[J].Blood Coagul Fibrinolysis,2004,15(7):583-591.
  • 5陈灏珠 主编.实用内科学[M].北京:人民卫生出版社,2003.1866.
  • 6Baue AE,Faist E,Donald E,主编,陈孝平,冷希圣主译.多器官衰竭[M].北京:人民卫生出版社,2004:26-28.
  • 7Eisele B,Lamy M,Thijs LG,et al. Antithrombin Ⅲ in patients with severe sepsis : a randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized,placebo-controlled,double-blind trial with antithrombin Ⅲ in severe sepsis[J]. Intensive Care Med, 1998,24(7 ) : 663-672.
  • 8Opal S. New treatment in sepsis[J]. Biomed Prog, 1998,11 ( 1 ) : 52-56.
  • 9Dellinger RP,Levy MM,Rhodes A. Surviving Sepsis Campaign:international guidelines for management of severe sepsis and septic shock,2012[J].Intensive Care Medicine,2013.165-228.
  • 10章雯静.乌司他丁的临床应用进展[J].中国新药杂志,2003,12(6):426-428. 被引量:33

共引文献2054

同被引文献114

  • 1赵利,程青虹,曾建琼,何永来,张忠双,张海俊.乌司他丁对脓毒症肺损伤大鼠HO-1表达的影响及保护作用[J].中国老年学杂志,2014,34(4):992-994. 被引量:4
  • 2景炳文.乌司他丁在急危重症临床应用的进展[J].中国危重病急救医学,2006,18(2):117-120. 被引量:127
  • 3刘清泉.对脓毒症中医病机特点及治法的认识[J].北京中医,2007,26(4):198-200. 被引量:200
  • 4Kelly H,Ngou J,Sawadogo B,et al.P3.223 HPV genotype distribution in HIV-positive african women and associations with high grade histological lesions by CD4+count[J].Sex Transm Infect,2013,89(1):218.
  • 5Nagaredddy P,Smyth SS.Inflammation and thrombosis in cardiovascular disease[J].Curr Opin Hematol,2013,20(5):457.
  • 6Martin FA,Murphy RP,Cummins PM.Thrombomodulin and the vascular endothelium:insights into functional,regulatory,and therapeutic aspects[J].Am J Physiol Heart Circ Physiol,2013,304(12):1 585.
  • 7DU B,AN Y,KANG Y,et al.Characteristics of critically ill patients in ICUs in China's Mainland[J].Crit Care Med,2013,41(1):84-92.
  • 8BRIERLEY J,PETERS M J.Distinct hemodynamic patterns of septic shock at presentation to pediatric intensive care[J].2008,122(4):752-759.
  • 9RONE R C.Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome:what we do and do not know about cytokine regulation[J].Crit Care Med,1996(24):163-172.
  • 10AIBIKI M,COOK J A.Ulinastatin,a human trypsin inhibitor,inhibits endotoxin-induced thromboxane B2production in human monocytes[J].Crit Care Med,1997,25(3):430-434.

引证文献12

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部